Home・Listă Acțiuni・Merck & Co Inc.

Merck & Co Inc.

Închisă

SectorSănătate

130.3 -0.41

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

129.69

Maxim

132.76

Indicatori cheie
By Trading Economics
Venit	-7.2B -4.2B
Vânzări	-114M 16B
P/E Medie Sector	35.992 68.51
EPS	-1.28
Randament dividend	2.52
Marjă de profit	-26.053
Angajați	73,000
EBITDA	-6.4B -2B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+6.13% upside

Dividende
By Acuity
Randament dividend Medie Sector	2.52% 2.29%
Următoarele câștiguri	29 oct. 2026
Data viitoare de dividende	7 oct. 2026
Următoarea dată ex-dividende	15 sept. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	35B 307B
Deschiderea anterioară	130.71
Închiderea anterioară	130.3

Sentimentul știrilor

By Acuity

52%

48%

247 / 340 Clasament în Healthcare

Merck & Co Inc. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 aug. 2026, 19:36 UTC

Social Media

News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7 aug. 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6 aug. 2026, 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5 aug. 2026, 19:43 UTC

News

Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4 aug. 2026, 23:26 UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3 aug. 2026, 20:03 UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 iul. 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 iul. 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 iul. 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 iul. 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 iul. 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24 iul. 2026, 18:56 UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22 iul. 2026, 19:46 UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21 iul. 2026, 19:56 UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20 iul. 2026, 20:02 UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Comparație

Modificare preț

Merck & Co Inc. Așteptări

Obiectiv de preț

By TipRanks

6.13% sus

Prognoză pe 12 luni

Medie 138.94 USD 6.13%

Maxim 155 USD

Minim 100 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMerck & Co Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

17 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 17 analiști care au acordat evaluări ale acțiunilor Merck & Co Inc. - Dist în ultimele 3 luni.

Sentiment

By Acuity

247 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.